Manning Paul B insider trades
Manning Paul B has filed 42 Form 4s with the SEC that we hold, for Candel Therapeutics, Inc. (CADL) (Director), Liquidia Corp (LQDA) (Director), Taysha Gene Therapies, Inc. (TSHA) (10% owner) and Verrica Pharmaceuticals Inc. (VRCA) (Director, 10% owner), among 5 companies in all. Across all of them we count 30 purchases worth $89.8M and 9 sales worth $31.7M reported on Form 4. In the last 12 months: 3 purchases ($20.5M) and 5 sales ($12.8M). The largest single trade was a purchase of 16,466,667 shares of Taysha Gene Therapies, Inc. worth $14.8M, dated 2023-08-16. The first filing on our record is dated 2021-07-08 and the latest 2026-10-02.
Candel Therapeutics, Inc. (CADL)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-07-27 | P, purchase reported on Form 4 | 36,000 | $265.0K | 2021-07-29 |
| 2021-07-29 | P, purchase reported on Form 4 | 1,625,000 | $13.0M | 2021-08-04 |
| 2021-07-29 | P, purchase reported on Form 4 | 20,000 | $146.0K | 2021-07-29 |
| 2024-12-16 | P, purchase reported on Form 4 | 500,000 | $3.0M | 2024-12-18 |
| 2024-12-16 | P, purchase reported on Form 4 | 750,000 | $4.5M | 2024-12-18 |
| 2026-02-23 | P, purchase reported on Form 4 | 550,458 | $3.0M | 2026-02-26 |
Liquidia Corp (LQDA)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-04-18 | P, purchase reported on Form 4 | 392,156 | $2.0M | 2022-04-19 |
| 2023-12-14 | P, purchase reported on Form 4 | 279,330 | $2.0M | 2023-12-18 |
| 2024-09-12 | P, purchase reported on Form 4 | 337,078 | $3.0M | 2024-09-16 |
| 2025-08-28 | S, sale reported on Form 4 | 154,337 | $4.3M | 2025-09-02 |
| 2025-08-29 | S, sale reported on Form 4 | 188,232 | $5.2M | 2025-09-02 |
| 2025-09-02 | S, sale reported on Form 4 | 74,230 | $2.2M | 2025-09-02 |
| 2025-09-02 | S, sale reported on Form 4 | 254,038 | $7.3M | 2025-09-02 |
| 2026-06-04 | S, sale reported on Form 4 | 19,125 | $1.2M | 2026-06-08 |
| 2026-06-04 | S, sale reported on Form 4 | 68,265 | $4.4M | 2026-06-08 |
| 2026-06-04 | S, sale reported on Form 4 | 88,487 | $5.7M | 2026-06-08 |
| 2026-06-04 | S, sale reported on Form 4 | 11,513 | $726.8K | 2026-06-08 |
| 2026-06-04 | S, sale reported on Form 4 | 12,610 | $812.3K | 2026-06-08 |
Taysha Gene Therapies, Inc. (TSHA)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-11-23 | P, purchase reported on Form 4 | 20,000 | $250.8K | 2021-11-24 |
| 2021-11-24 | P, purchase reported on Form 4 | 2,202 | $29.0K | 2021-11-29 |
| 2022-02-02 | P, purchase reported on Form 4 | 22,000 | $170.9K | 2022-02-04 |
| 2022-02-02 | P, purchase reported on Form 4 | 58,000 | $450.7K | 2022-02-04 |
| 2022-02-02 | P, purchase reported on Form 4 | 45,000 | $349.6K | 2022-02-04 |
| 2022-02-03 | P, purchase reported on Form 4 | 26,602 | $208.6K | 2022-02-04 |
| 2022-02-03 | P, purchase reported on Form 4 | 50,000 | $392.0K | 2022-02-04 |
| 2022-10-31 | P, purchase reported on Form 4 | 1,500,000 | $3.0M | 2022-11-02 |
| 2023-08-16 | P, purchase reported on Form 4 | 16,466,667 | $14.8M | 2023-08-16 |
| 2023-11-17 | P, purchase reported on Form 4 | 100,000 | $163.0K | 2023-11-20 |
| 2024-06-27 | P, purchase reported on Form 4 | 1,333,333 | $3.0M | 2024-07-01 |
| 2025-05-30 | P, purchase reported on Form 4 | 750,000 | $2.1M | 2025-06-03 |
Verrica Pharmaceuticals Inc. (VRCA)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-12-02 | P, purchase reported on Form 4 | 30,023 | $283.7K | 2021-12-06 |
| 2021-12-03 | P, purchase reported on Form 4 | 19,977 | $184.2K | 2021-12-06 |
| 2022-07-05 | P, purchase reported on Form 4 | 4,761,904 | $10.0M | 2022-07-05 |
| 2023-07-24 | P, purchase reported on Form 4 | 200,000 | $1.0M | 2023-07-24 |
| 2024-11-22 | P, purchase reported on Form 4 | 4,494,382 | - | 2024-11-26 |
| 2024-11-22 | P, purchase reported on Form 4 | 18,426,966 | - | 2024-11-26 |
| 2025-11-25 | P, purchase reported on Form 4 | 1,375,380 | $5.8M | 2025-11-25 |
| 2025-11-25 | P, purchase reported on Form 4 | 2,750,762 | $11.7M | 2025-11-25 |
Acumen Pharmaceuticals, Inc. (ABOS)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-07-06 | P, purchase reported on Form 4 | 312,500 | $5.0M | 2021-07-08 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1494695) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms